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Abstract 
Medical Insurance and Free Choice of Physician Shape Patient Over-
treatment. A Laboratory Experiment* 
 
 
In a laboratory experiment designed to capture key aspects of the interaction be-
tween physicians and patients, we study the effects of medical insurance and 
competition in the guise of free choice of physician, including observability of 
physicians’ market shares. Medical treatment is an example of a credence good: 
only the physician knows the appropriate treatment, the patient does not. Even 
after a consultation, the patient is not sure whether he received the right treat-
ment or whether he was perhaps overtreated. We find that with insurance, moral 
hazard looms on both sides of the market: patients consult more often and physi-
cians overtreat more often than in the baseline condition. Competition decreases 
overtreatment compared to the baseline and patients therefore consult more of-
ten. When the two institutions are combined, competition is found to partially 
offset the adverse effects of insurance: most patients seek treatment, but over-
treatment is moderated. 
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1. Introduction 
We study the economic incentives emanating from two key institutions in the medical market –
competition and insurance – conceptualizing interaction as the provision of a credence good. 
Markets for credence goods are characterized by a high degree of asymmetric information 
between those supplying and those demanding the good or service. Medical treatments are a 
prime example of credence goods, and an economically important one.1  
The specific interaction we study is as follows. A patient is confronted with a medical 
problem and chooses whether to consult a physician. The medical problem can be severe in 
which case only a severe (and costly) treatment can provide a cure. Alternatively, the problem 
could be mild, such that a mild (and cheap) treatment is sufficient for a cure. Information about 
the type of problem is asymmetric: after examining the patient the physician knows what kind 
of treatment the patient needs, but the patient does not. We induce incentives for 
overtreatment (that is, to provide the severe treatment when the problem is in fact mild) by 
choosing experimental parameters such that the physician makes more money from the severe 
treatment. Reputational incentives disciplining physicians are weak because the patient only 
learns that he has been cured, but not whether the treatment he received was appropriate.2 
Such markets are likely to be beset by overtreatment and low efficiency.3 
We study how basic forms of medical insurance and competition shape overtreatment 
and other outcomes in this setting. We study competition in the guise of patients being able to 
freely choose among physicians.4 This type of competition has been shown to be rather 
effective in markets for experience goods (Huck et al. 2012). Competition has bite in such 
markets because reputational incentives are strong and can discipline sellers to provide good 
quality. But with credence goods, building effective reputations is difficult because patients 
cannot tell whether a severe treatment was necessary. Nevertheless, we find that competition 
                                                     
1 Other examples of credence goods are car repairs (e.g. Schneider 2012) or taxi rides in a foreign city (e.g. 
Balafoutas et al. 2014). Both studies provide field experimental evidence. For an overview of the theoretical 
literature, see Dulleck and Kerschbamer (2006). The seminal paper on markets for credence goods is Darby and 
Karni (1973). 
2  A key difference between credence and experience goods is that overcharging or overprovision cannot easily be 
detected (see Dulleck et al. 2011 for a discussion). 
3 Iizuka (2007) for instance reports evidence from the Japanese prescription drug market where physicians do not 
only prescribe but also dispense drugs. They show that prescriptions are to some extent influenced by mark-ups 
and hence not only by factors that are relevant to the patient’s state of health.   
4 Note that this type of non-price competition is typical for patient-physician interactions in which prices are 
regulated. See Huck et al. (2016) for an experimental study of price competition in a market for experience 
goods. We use “competition” and “free choice of physician” interchangeably in the remainder of the paper. 
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has surprisingly strong beneficial effects. It clamps down on overtreatment (the incidence falls 
by about two thirds) encouraging patients to consult more often as they can now be more 
confident not to be overtreated. 
The second institution we investigate is insurance. We expect insurance to invite moral 
hazard, as it shields the individual patient from the adverse monetary consequences of 
overtreatment. The insurance we study socializes the cost of overtreatment. As physicians 
anticipate or become aware that patients are less wary under the umbrella of insurance, they 
have an additional incentive to overtreat. We expect reduced wariness to mitigate the 
disciplining effect of reputational concerns. Indeed, this is what we find: the consultation rate is 
much higher with insurance than in the baseline, and overtreatment is more common as a 
consequence.  
By virtue of a 2-by-2 design we can also study interaction effects. We find that 
competition has powerful effects both in the absence and in the presence of insurance. In the 
latter case, competition cuts overtreatment in half and boosts the share of consulting patients. 
Thus, competition partly mitigates the adverse effect of insurance while keeping incentives to 
consult strong. As a result, the combination of both institutions produces the highest level of 
public health among the institutional settings studied here. This combination is however also 
associated with the highest expenditures for health (measured by the total transfer from 
patients to physicians). At least in the setting studied here, it does not seem possible to 
decrease expenditures without decreasing public health at the same time.  
In our experimental design, competition involves observability of market shares. Patients 
do not only have the possibility to choose the physician they want to interact with but they can 
also observe by how many other patients a physician has been consulted in the past. Hence, we 
can only draw conclusions about the joint impact of competition and observability of market 
shares. To be able to disentangle these two effects, we conduct two additional control 
treatments in which patients are able to choose their physician but market shares cannot be 
observed. The results of these control treatments indicate that the positive impact of 
competition is mainly driven by free choice and not by observability. In the remainder of the 
paper,  we focus on our four main treatment conditions 5 and describe the additional 
treatments as well as their results in Sections 4.3 and 4.4.  
                                                     
5  We will use the expression “impact of competition” as a synonym for the impact of competition in the guise of 
“informed choice,” i.e. for the joint impact of being able to choose a physician (“pure competition”) and the 
observability of market shares. The primary reason to focus on the main treatment conditions is to keep the 
structure of the paper clear and concise. Moreover, it seems sensible to vary the observability of market shares 
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We think our results speak to ongoing debates about how to devise efficient systems in 
health care. Free choice of physician and the availability of medical insurance are among the 
most relevant institutional choices to make in the design of a health care system. For example, 
there is an ongoing debate in various countries whether elements of co-payment should be 
increased to overcome moral hazard problems associated with health insurance. Health care 
systems also strongly differ by the degree to which patients are allowed to choose their 
physician: With a general practitioner-centered model, patients are usually assigned to a 
physician in their district and possibilities to consult different physicians are restricted – in 
contrast to health care systems with free choice of physician. We think that our study sheds 
new light on these important debates by virtue of the ability to measure and control important 
aspects of the patient-physician interaction. For example, we unambiguously observe all 
instances of overtreatment and we control the cost it entails. In the field, overtreatment often 
goes unnoticed and its costs can only be roughly estimated. Our treatment variations also allow 
us to isolate the effects of institutional changes to a much higher degree than is possible in the 
field. However, circumspection is advised in extrapolating from our highly stylized setting to the 
actual policy debate which is embedded in a rich medical-technical, institutional, and cultural 
context. Such context-specific aspects may or may not matter for the interaction of patient and 
physician. What we provide here is an analysis of how economic incentives emanating from 
controlled but highly stylized institutional changes shape overtreatment in an environment that 
is conducive to it.  
Related literature. Our study is related to various streams of literature. First, it 
contributes to the recently emerging literature in experimental health economics. A series of 
laboratory experiments (Brosig-Koch et al. 2013a, 2013b, Hennig-Schmidt et al. 2011, Kairies 
and Krieger 2013, Keser et al. 2014, Keser et al. 2013, Green 2014) investigate incentive effects 
of remuneration systems for physician behavior. For example, Hennig-Schmidt et al. (2011) 
compare a capitation system (in which the physician gets paid per patient independent of the 
treatment provided) and a fee-for-service system (in which payment does depend on the 
treatment provided). They find that subjects react to the incentives of the payment system – 
leading to substantial levels of under- and overtreatment – and that this is also the case for 
medical students. In contrast to our study, which focuses on patient-physician interaction, 
patients make no choices in their experiment (their payoffs are modeled by donations to a 
medical charity that uses the money for medical treatment of real patients). Their finding that 
                                                                                                                                                                           
and pure competition at the same time. Patients can only react to the market shares they observeif they are 
able to choose a physician in the first place. The presence of pure competition should therefore promote the 
emergence of institutions facilitating the observability of markets shares. 
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financial incentives shape the treatment physicians provide is also supported by various 
empirical studies using field data (see e.g. Clemens and Gottlieb 2014, Devlin and Sarma 2008 
or Sørensen and Grytten 2003). Another example for a health economic experiment is Schram 
and Sonnemans (2011) who study the demand side of a health insurance market, i.e. how 
subjects choose a health insurance policy in a complex decision environment. Buckley et al. 
(2012) investigate the interplay of public and private health insurance in a revealed-choice 
experiment. 
Our experiment is also related to a stream of experimental literature investigating 
credence goods, in particular Beck et al. (2013, 2014) and Mimra et al. (2013, 2014). A close 
match to our study is Dulleck et al. (2011). These authors study a market for credence goods in 
a flexible and broad setting that allows them to analyze various institutional frameworks and 
various aspects of market failure in the provision of credence goods. For example, they allow 
for overtreatment (as we do), in addition to overcharging and undertreatment. These 
phenomena are particularly relevant in markets for car repairs but less characteristic of many 
markets for medical treatments. We therefore focus on a framework with fixed prices and 
overtreatment that fits the patient-physician interaction and allows us to study relevant 
institutions like health insurance and free choice of physician. Mimra et al. (2013) is also closely 
related to our paper. These authors study the effect of price competition compared to fixed 
prices. They find that the level of supplier opportunism (in their case undertreatment and 
overcharging) is significantly higher in a market with price competition than in a market with 
fixed prices. In contrast to their study, we compare competition with fixed prices to a situation 
with fixed assignment (i.e. random repeated matching) which is particularly relevant in a 
market for medical treatments. 
There are only a few experimental studies investigating the effects of free choice of 
interaction partner based on reputation. Huck et al. (2012, 2016) and Bolton et al. (2008) study 
free choice of seller in a market for experience goods, Dulleck et al. (2011) and Mimra et al. 
(2013) in a market for credence goods (in their setting, competition is based both on reputation 
and prices). The main finding of these studies is that competition with fixed prices decreases 
opportunistic seller behavior whereas price competition pushes prices down but increases 
opportunism at the same time. In the health context, several empirical studies suggest that free 
choice of the health-care provider has beneficial effects on market performance. For example, 
Cooper et al. (2011) find that a reform in the English National Health Service reduced mortality 
significantly by giving patients the freedom of choice which hospital they want to be transferred 
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to. Kalda et al. (2003) and Schmittdiel et al. (1997) find that giving patients the option to choose 
the physician providing primary care leads to higher overall patient satisfaction. 
A series of empirical studies estimate the extent to which the demand for medical 
services is related to the extent of insurance coverage, e.g. the co-payment rate. Examples are 
Scitovsky and Snyder (1972), Manning et al. (1987), and Aron-Dine et al. (2013). Most of these 
studies find that increased co-payment reduces the demand for medical services. Chiappori et 
al. (1998) provide a particularly convincing study on this matter. These authors analyze data 
from a natural experiment where a co-payment rate of 10% was introduced for one group of 
patients but not for a control group of patients. They find that the number of home visits 
decreases significantly with the co-payment rate but find no effect for the number of office 
visits. Sülzle and Wambach (2005) provide a theoretical analysis of insurance in a market for 
credence goods with the possibility to search for second opinions. They show that a higher rate 
of co-insurance can have two opposite effects. It can either lead to less fraud and less search 
for second opinions or to more fraud and more search activities in the market. 
While the evidence above for insurance-induced moral hazard is rather abundant and 
quite compelling, we are not aware of evidence on supply-side responses to such moral hazard 
(i.e. to what extent physicians provide more services than necessary if they anticipate that 
patients care less about getting excessive treatments because the costs are covered by 
insurance). Such responses could be called “second-order moral hazard” and Balafoutas et al. 
(2013) provide evidence for it in the context of taxi rides in Athens. They find that if a passenger 
indicates to the driver that the bill is paid by their employer, passengers are significantly more 
likely to be overcharged compared to a control group giving no such indication.  
We proceed as follows. Section 2 describes the experimental design, section 3 derives 
predictions for the effects of competition and insurance, section 4 presents results, and section 
5 concludes. Appendix A provides instructions, B screenshots, and appendices C to H provide 
complementary tables, figures and analyses.   
2. Experimental Design 
Before going into a detailed description of treatment conditions, parameters and procedures, 
we now provide a short overview of the design.  
In all conditions, experimental subjects are randomly assigned to a fixed role as physician 
(the seller or provider of the treatment who is called “adviser” in the experiment) or patient 
(the buyer or demander of the treatment who is called “client” in the experiment) at the 
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beginning of the experiment and they interact repeatedly. Patients know that they have a 
problem (mild or severe) and need a treatment, but they do not know what treatment they 
need. In contrast, physicians do know what type of treatment the patients need. Patients 
choose whether or not to consult a physician. The material incentives in our experiment are 
stacked against providing the correct treatment when the patients need a mild treatment, i.e. 
physicians have strong incentives to overtreat patients. Reputational incentives to provide 
proper treatment are weak because the patients cannot unambiguously infer whether they got 
the treatment they needed or whether they were overtreated.  
Starting from this baseline condition, we investigate the effects of two simple institutions, 
competition and insurance, on overtreatment and other interaction outcomes (i.e. consulting 
rates, patients’ and physicians’ average earnings as well as two measures for efficiency). 
Competition means that patients can choose which physician they want to consult rather than 
being assigned randomly to a physician. Insurance means that the cost of treatment (or more 
precisely the additional cost of a severe treatment) is borne by all patients collectively rather 
than by one patient alone.  
Table 1: Main Treatments 
  Insurance 
  No Yes 
Competition 
No BASE n = 56 
INS 
n = 56 
Yes COMP n = 56 
INS-COMP 
n = 56 
Notes: We have 7 markets per main treatment. In each market, 5 patients and 3 physicians interact. 
The number of subjects in the main treatments is 224 (= 4 treatments x 7 markets x 8 participants). 
We have another 112 subjects in 2 control treatments described in section 4.3. 
 
Table 1 summarizes the design. We use a between-subject 2 x 2 factorial design and label 
the main treatments as follows: BASE (baseline condition), COMP (competition but no 
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insurance), INS (insurance but no competition) and INS-COMP (insurance and competition). We 
also ran two additional control treatments described in section 4.3.6  
2.1 Baseline condition 
We consider the interaction of three physicians and five patients in a market (i.e. a matching 
group).7 At the beginning of the experiment, subjects are randomly assigned to a role and 
market for the entire experiment which consists of 30 periods. At the beginning of each period, 
patients are randomly assigned to a physician in their market. Thus, each physician may find 
herself with between 0 and 5 patients assigned to her, and all or some of the patients assigned 
to her may also consult her.8  
Figure 1 shows the stage game between one physician and one patient who has been 
matched to her. The structure of moves and the payoffs are common information to all 
participants. At the beginning of each period, the severity of the patient’s problems is randomly 
determined (same draw for all patients). It is mild with probability 𝑞(𝑀) and severe with 
probability 𝑞(𝑆) = 1 − 𝑞(𝑀). When patients make the choice whether to consult (𝐶) or not to 
consult (¬𝐶), they are not aware of the severity of their problem (indicated by the information 
set marked with “Patient” in figure 1).  
In contrast, the physicians do know the severity of the patients’ problem and the number 
of patients consulting them.9 The physician then chooses the treatment (𝑚 or 𝑠) for the 
patients who have consulted her. Given a mild problem, the physician chooses whether to 
overtreat the patient, i.e. she has the option to provide a severe treatment (choose 𝑠 when the 
Problem is 𝑀, see left node marked with “Physician”). In case of a severe problem the physician 
cannot undertreat (e.g. decline to treat the patient). That is, in case of a severe problem, she 
has to provide the severe treatment 𝑠.10  
                                                     
6  To make the choices among suppliers effective, we provide information about market shares in COMP which is 
absent in BASE. That is, the effect of BASE vs. COMP (and INS vs. INS-COMP) is driven by “informed choice”.  We 
have run additional control treatments to disentangle the effect of (uninformed) choice of physician and of 
providing information about market shares alone, see section 4.3.  
7  Physicians are called “advisers” and patients are called “clients” in the experiment, see section 2.3 for 
explanations. 
8  We use female gender for physicians and male gender for patients throughout to facilitate understanding. 
9  Physicians also know the number of patients assigned to them but do not know the identity of the patients. 
10  The physician has to provide the same treatment to all patients who consulted her. The reason for assigning the 
same type of problem to all patients within one group is to make sure that the physician has always the 
possibility to provide the proper treatment to all consulting patients. 
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The payoff earned by a physician from interacting with one patient is shown in the last 
line of figure 1. The payoff is the price of treatment (which is assumed to be exogenously fixed 
and has to be paid by the patient to the physician) minus the cost of treatment: 𝑝(𝑖) − 𝑐(𝑖),
𝑖 𝜖 {𝑚, 𝑠}. The total payoff for one period is this number multiplied with the number of patients 
𝑘 who consulted the physician. Accordingly, the final payoff is zero if no patient consulted the 
physician. Note that the physician’s payoff results from actually treating the patient; just being 
matched generates no value for the physician. 
Figure 1: Baseline condition (stage game) 
 
 
The payoff earned by a patient depends on whether he decided to consult the physician 
or not. If the patient decides not to consult, his payoff depends on the severity of the 
“unsolved” problem. We make the rather plausible assumption that the patient’s payoff is 
lower when his unsolved problem is severe than when it is mild, i.e. 𝑣(𝑆, ¬𝐶) < 𝑣(𝑀, ¬𝐶). 
If a patient consults a physician, he will always receive a treatment so that his problem is 
solved for sure. The payoff of the patient is determined by the value of the treatment (which 
depends (for now) on the severity of the problem as well as the treatment provided) and the 
price of the treatment: 𝑣(𝑗, 𝑖) − 𝑝(𝑖), 𝑖 𝜖 {𝑚, 𝑠}, 𝑗 𝜖 {𝑀, 𝑆}.  
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The reputational incentives to mitigate overtreatment are rather weak given the feedback 
provided to patients. At the end of each period, the patient is informed about the treatment he 
got but not about the severity of his problem. He of course only learns about the treatment he 
got given that he consulted the assigned physician. In case the patient does not consult he gets 
to know the severity of the problem.11 
When making choices, subjects see a history table showing a summary of previous 
periods (see appendix B for screenshots). Physicians have fixed IDs which are revealed to 
patients, i.e. physicians are not anonymous to patients. In fact, when making the consulting 
choice, patients can see which physician they have been assigned to, whether they had 
consulted the assigned physician before and what treatment they had gotten from this 
physician (but do not learn the true severity of the problem they had). For periods in which the 
physician was not consulted, patients can see the severity of their problem (following the logic 
explained in footnote 10). When making the choice of what treatment to provide, physicians 
see the number of patients assigned to themselves, the severity of the patients’ problems in 
the current period and can review the same information for earlier periods, including what 
treatments they provided. 
In essence, the information provided in the history table means that patients can recall 
their own experiences with a physician but do not know about the experiences of other 
patients (or the treatments provided by non-consulted physicians). This seems plausible in the 
context of the interaction between patient and physician.12  
A characteristic feature of a credence good is that some quality uncertainty persists even 
after the purchase of the good. We study the type of credence good where the consumer does 
not know what he needs but can observe what he got.13 This type of credence good is 
particularly relevant for medical treatments: The patient can typically observe the treatment he 
                                                     
11  The reason for informing patients about the severity of their problem (after not consulting) is the following: If 
the patient decides not to consult, he does not receive a treatment and hence his problem is not solved. This 
implies that the patient experiences the consequences of his unsolved problem (e.g. suffers pain). But he 
suffers more in case of a severe problem (leading to a lower payoff). Therefore, non-consulting patients can 
infer the severity of the problem from their payoff (which they learn at the end of each period). In contrast, the 
problem is solved (i.e. he is cured) if the patient consults a physician and receives a treatment. He can therefore 
not infer whether the problem was severe or mild. 
12  The information conditions here parallel the treatment with private information (pi-nc) in Huck et al. (2012).  
13  The literature (see Dulleck et al. 2011 for a discussion) distinguishes between this type of credence good and a 
second type (clients know what they want but not what they got). The second type refers to goods where 
consumers have strong preferences over certain characteristics of a product (like environmentally friendly 
production) that can however not easily be observed after the purchase. 
10 
 
received from his physician but he is uncertain about his health condition, i.e. what kind of 
treatment he needs. To parallel the logic in the field context, it is therefore important that the 
patient cannot determine ex post whether a severe treatment was actually necessary due to a 
severe problem or whether he was overtreated (i.e. a mild treatment would have been 
sufficient). To guarantee that this is the case, the payoff from a severe treatment needs to be 
independent of the actual severity of the problem (otherwise the patient could easily infer 
whether the severe treatment was necessary or not): 
𝑣(𝑀, 𝑠) − 𝑝(𝑠) = 𝑣(𝑆, 𝑠) − 𝑝(𝑠)   ⇔    𝑣(𝑀, 𝑠) = 𝑣(𝑆, 𝑠) 
Furthermore, we choose the parameters such that the sum of the patient’s and 
physician’s payoff is independent of the treatment provided by the physician: 
𝑣(𝑀,𝑚) − 𝑝(𝑚) + 𝑝(𝑚) − 𝑐(𝑚) = 𝑣(𝑀, 𝑠) − 𝑝(𝑠) + 𝑝(𝑠) − 𝑐(𝑠) 
This choice enhances our experimental control as it allows us to exclude a concern for 
efficiency as a motive for the physician’s choice of treatment. As a consequence of our 
parameter choices, overtreatment (i.e. providing a severe treatment in case of a mild problem) 
is not associated with an efficiency loss; it is a pure redistribution from the patient to the 
physician.14 
We choose parameters such that the appropriate treatment in case of a mild problem 
(i.e. the mild treatment) generates at least as much value as the inappropriate (severe) 
treatment, i.e. 𝑣(𝑀,𝑚) ≥ 𝑣(𝑀, 𝑠), and that the cost of a severe treatment are at least as high 
as the cost for a mild treatment, i.e. 𝑐(𝑠) ≥ 𝑐(𝑚). Given these choices, it follows that 
𝑣(𝑀, 𝑠) = 𝑣(𝑀,𝑚) and  𝑐(𝑠) = 𝑐(𝑚).15 Essentially, the fact that 𝑣(𝑀, 𝑠) = 𝑣(𝑀,𝑚) = 𝑣(𝑆, 𝑠) 
means that receiving a treatment solves the medical problem (i.e. the patient is cured), and this 
is independent of whether the problem was severe or mild. Thus, we assume that there are no 
adverse health effects from being overtreated.  
                                                     
14  This choice is not motivated by parallelism to medical practice (overtreatment may for instance cause 
inefficiency in the presence of capacity constraints for severe treatments) but for methodological reasons.  The 
absence of efficiency losses allows us to implement a clear-cut case of a credence good: payoffs after being 
overtreated and after receiving a necessary severe treatment are identical. Therefore, patients cannot identify 
from inspection of their payoffs whether they received the correct treatment or not. Since we hold this 
property constant across all conditions it does not affect the interpretation of treatment comparisons. 
15  It would not be correct to infer from this that overpricing is entirely isomorphic to overtreatment, the case we 
discuss here. The reason is that we assume that only a severe treatment can solve a severe problem, indicating 
that a severe and a mild treatment differ not only in price. 
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2.2 Treatments with Insurance and Competition 
The insurance condition is identical to the baseline condition except for patients’ payoffs. In the 
baseline condition, a consulting patient’s payoff depends only on the treatment he got. The 
downside of being overtreated results from (unnecessarily) having to pay a higher price. In the 
insurance conditions, the patient is shielded from (i.e. insured against) incurring the additional 
cost of being overtreated. Specifically, the additional costs of a severe treatment are socialized 
in the sense that they are borne by all patients collectively rather than by the overtreated 
patient alone.  
All patients pay an insurance premium to cover the additional costs of overtreatment; this 
premium depends on the total number of severe treatments within a market 𝑛(𝑠) and it is used 
to pay the price difference between a mild and a severe treatment ( 𝑝(𝑠) − 𝑝(𝑚) ). Note that 
patients who do not consult a physician also pay this premium. The premium is therefore the 
total additional spending for severe treatments divided by the total number of patients in one 
market ( 𝑁 ): 
𝑃(𝑛(𝑠)) = 𝑛(𝑠)
𝑁
∙ �𝑝(𝑠) − 𝑝(𝑚)� 
A patient’s payoff for refraining from consulting is 𝑣(𝑆, ¬𝐶) − 𝑃(𝑛(𝑠)) for a severe 
problem and  𝑣(𝑀, ¬𝐶) − 𝑃(𝑛(𝑠)) for a mild problem. If the patient decides to consult a 
physician, his payoff is 𝑣(𝑗, 𝑖) − 𝑝(𝑚) − 𝑃(𝑛(𝑠)), 𝑖 𝜖 {𝑚, 𝑠}, 𝑗 𝜖 {𝑀, 𝑆}. While this expression 
can turn negative, we cap patients’ payoffs at zero to prevent loss aversion to shape behavior. 
The calculation of payoffs for physicians is identical to the baseline condition. As 
explained above,  𝑣(𝑀, 𝑠) = 𝑣(𝑀,𝑚) = 𝑣(𝑆, 𝑠). This means that the individual payoff of a 
patient does – in contrast to the baseline condition – no longer depend on which treatment he 
gets. The only effect of overtreatment is that it boosts the insurance premium which has to be 
paid by all patients in the market collectively (also those who did not consult a physician). 
Because patients are informed about how the insurance premium is calculated and learn 
the premium they have to pay at the end of every period in INS, patients do not only get to 
know the treatment they received themselves (as in BASE) but can also infer the total number 
of severe treatments within the market from their final payoff. However, as in BASE, they are 
not informed about the true severity of their problem (or the severity of the problem of other 
patients). Note that the insurance premium is calculated to be fair (covers all costs but does not 
generate surplus).  
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The treatments with competition (COMP and INS-COMP) differ from those without 
competition (BASE and INS, respectively) in two ways. The first is that patients now can choose 
freely which physician to consult. The matching of patients and physicians is thus not random as 
in BASE (and INS) but endogenous. In treatments with competition, patients do not only decide 
whether to consult a physician but also which one to consult. The second difference concerns 
information. With competition (i.e. in COMP and INS-COMP), both patients and physicians see 
the market shares, i.e. the number of patients having consulted a particular physician in 
previous periods in the history table. The effect of treatment variation in the main treatments 
(i.e. BASE vs. COMP and INS vs. INS-COMP) thus measures the effect of introducing what we will 
call “informed choice” or “informed competition” below. Making such information available 
quite plausibly boosts the effect of physician choice, and vice versa. Because we need to limit 
the duration of the experiment for practical reasons (e.g. to prevent subject fatigue), it is 
difficult for physicians to effectively form reputations and for patients to reliably infer them 
within the time of interaction available (30 periods). Access to such information in the field 
seems plausible. Patients can often observe whether a physician is in high demand (they can 
e.g. observe the length of the waiting list or how full the waiting room is). While we think the 
effect of “informed choice” is highly relevant, we also ran two control treatments to isolate the 
effect of choice of physician when market shares cannot be observed (COMP_nms and INS-
COMP_nms, see section 4.3). 
2.3 Experimental procedures and parameters 
The experiment was conducted using the software z-tree (Fischbacher 2007) with a total of 336 
undergraduate students from various disciplines at the University of Copenhagen as subjects 
(224 in the main treatments and 112 subjects in the two control treatments, see section 4.3)16. 
Subjects were recruited using the online recruiting system ORSEE (Greiner 2015) and each 
subject participated in one session only. At the beginning of the experiment, subjects were 
seated randomly in the laboratory and received written instructions (see appendix A) explaining 
the experiment. The language of the instructions was kept neutral. We did not frame the 
situation in a medical context. Instead of “physician” and “patient”, we used the terms 
“adviser” and “client”, and explained that the latter was confronted with a problem that could 
either be mild or severe.  
                                                     
16  Henning Schmidt and Wiesen (2014) show that medical students behave more pro-socially than students from 
other fields when a game broadly akin to ours is framed in terms of provision of medical treatments.  
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In a laboratory experiments, such framing may be important. Previous studies find that 
changing a single word (Dufwenberg et al. 2011) or the labelling of actors (Huck et al. 2004) can 
result in a remarkable difference in behavior. Engel and Rand (2014) find that subjects might 
project their own frame when they are confronted with a decontextualized decision situation, 
leading to differences in behavior if the background of the experiment does not coincide with 
the projected frames. We choose the somewhat colorful terms “problem”, “adviser”, and 
“client” to find a compromise between the particularly loaded medical framing on the one hand 
and abstract expressions like “A-participant” and “B-participant” on the other hand. As an 
alternative to abstract expressions, the main purpose is to facilitate subjects’ understanding of 
instructions in a rather complex set-up. We have decided not to use a medical framing for the 
following reasons: First, it allows us to interpret our findings also in the context of other market 
for credence goods (like car repair services), so that we are able to contribute to the 
experimental literature on markets for credence goods as well (where the instructions generally 
use a neutral framing, see for instance Dulleck et al. 2011). Second, the medical framing seems 
more important in situations where undertreatment can be chosen by suppliers and where the 
consequences for a patient might be suffering or even death. Such outcomes are, of course, 
much harder to capture through purely monetary incentives. The focus of our study is, 
however, on overtreatment (think of a radiologist deciding on whether to employ a harmless, 
expensive and wholly unnecessary scanning procedure to increase his payout). The decision to 
overtreat a patient with a harmless procedure is in our view mainly an economic rather than a 
medical decision. After all, the patient is cured with or without overtreatment.    
Moreover, we are mainly interested in treatment differences rather than absolute levels 
of behavior. Assuming that there is no interaction effect between the labelling of actors in the 
instructions and the analyzed institutions, framing should only play a minor role. This 
assumption is supported by the fact that none of the papers investigating the impact of a 
medical vs. a non-medical framing (see for instance Ahlert et al. 2012, Boehm et al. 2015) finds 
a notable interaction effect between the framing and other treatment variations.17 
Our experimental design differs in one other important dimension from previous 
economic experiments investigating how physicians treat their patients. In these studies 
(Hennig-Schmidt et al. 2011 is the first study implementing this method), patients do not play 
an active role in the experiment, as the level of treatment provided by the physician is modeled 
                                                     
17  One exception is Kesternich et al. (2015) who find that a Hippocratic Oath is more effective with the medical 
framing. However, this treatment variation is directly related to the medical framing, which is not the case for 
our treatment variations.  
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as a contribution to a charity with a medical background (i.e. the higher the level of treatment 
chosen by the physician the higher the resulting donation to the charity and, as a 
consequence,the level of treatment received by real patients taken care of by the charity). This 
approach has certainly the advantage that physicians’ actions do influence the well-being of 
actual patients which (in combination with the medical framing) increases ecological and 
external validity. 
A limitation of this method is that patients have no active role in the experiment. An 
actual interaction between patient and physician is therefore not possible. This is not much of 
an issue in the studies mentioned above, as their focus is on physicians’ behavioral responses 
toward changes in the incentive structure of the remuneration system.  In contrast, one of the 
main goals of our experiment is to study competition in the guise of free choice of physician in a 
market for medical services. This requires actual interaction between physicians and patients 
and to model the latter as active participants in the laboratory. 
On average, one session lasted about 75 minutes and subjects earned 212 DKK (≈ 28.4 
EUR), including a show-up fee of 75 DKK. The severity of the patients’ problem was determined 
randomly (with overall proportions of 1/3 and 2/3) for each market and period in the baseline 
condition in preparation of the experiment. The same sequences were then also used for the 
markets in the other conditions (i.e. each market in a given condition had the same order of 
periods with mild and severe treatment as another market in the other three conditions).  
Figure 2 shows the parameters: The probability of a mild problem is 𝑞(𝑀) = 2
3
 , and that of a 
severe problem is 𝑞(𝑆) = 1
3
.18 The patient’s benefit if his problem is solved is  𝑣(𝑀, 𝑠) =
𝑣(𝑀,𝑚) = 𝑣(𝑆, 𝑠) = 25. 19 Note that this benefit is independent of the treatment and the 
severity of the problem. The costs of providing a severe treatment (which are identical to the 
costs of providing a mild treatment) are  𝑐(𝑠) = 𝑐(𝑚) = 5. The price (to be paid by the patient 
to the physician) is  𝑝(𝑚) = 15 for a mild treatment, and 𝑝(𝑠) = 22  for a severe treatment. 
                                                     
18  We chose the mild problem to occur twice as often as the severe problem because only periods with a mild 
problem are interesting with respect to overtreatment. While the periods with a severe problem are not 
interesting in themselves (physicians are forced to provide the severe treatment and therefore have no real 
choice to make), they are an essential element of the design to maintain patients' ex-post uncertainty about 
whether the treatment was necessary. 
19  The payoffs in the experiment are determined by the difference between price and cost (for physicians) and the 
difference between the value of treatment and the price (for patients). The suggested parameter values are for 
illustration purposes only; adding a constant to all parameter values would lead to the same payoffs in the 
experiment. 
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Hence, the physician’s payoff for treating one patient is 17 in case of a severe treatment and 10 
in case of a mild treatment. 
Her final payoff for one period results from multiplying this number with the total number 
of patients 𝑘 consulting her. The patient’s payoff from receiving a severe treatment is 3 (and 10 
for a mild treatment, respectively). In case the patient does not consult the physician, his payoff 
is 𝑣(𝑆, ¬𝐶) = 2 in case of a severe problem and 𝑣(𝑀, ¬𝐶) = 9 in case of a mild problem. Note 
that our choice of parameters implies that the patient’s benefit of receiving the correct 
treatment vs. no treatment is small (1 point) while his cost (and the physician’s incentive to 
overtreat) is rather big. This choice of parameters has the advantage that a positive effect of 
competition, if any, is underestimated rather than overestimated. Our choice of parameters is 
also driven by the concern to provide an informative baseline condition. To be able to detect 
any (beneficial and harmful) effects of the institutions under consideration, the baseline needs 
to be calibrated such that consulting and overtreatment are at intermediate levels, i.e. that 
there is sufficient room for improvement and for deterioration. 
Figure 2: Extensive form (baseline condition, with actual payoffs) 
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3. Predictions and hypotheses 
This section derives theoretical predictions and formulates hypotheses regarding expected 
treatment differences. We derive equilibria in the stage game for the baseline condition (section 
3.1), the conditions with insurance (3.2), and we discuss the condition with competition (3.3). 
Based on the results in previous studies, we expect the treatment differences to be smaller than 
predicted by standard theory but to be qualitatively in line with standard theory. 
3.1 Predictions for the baseline condition (BASE) 
If we assume common knowledge of rationality and strict self-interest, we can solve the game in 
the baseline condition (see figure 2) by backward induction. Given that the physician will always 
provide the severe treatment, the patient’s expected payoff for consulting is always lower than 
the expected payoff of not consulting.  In the unique equilibrium20 patients do therefore not 
consult (and physicians provide a severe treatment if they get the chance to do so – which they 
do not along the equilibrium path).  
From a behavioral perspective, we expect the consulting rate in the baseline condition to 
be low, but not to be zero as predicted under the standard assumptions. In fact, the 
experimental evidence from repeated trust games (see e.g. Bolton et al. 2004) reveals a 
substantial level of trust in initial periods which eventually fades. Yet, two aspects of our design 
lead us to expect lower consulting rates compared to previous experiments on repeated trust 
games. First, in markets for credence goods it is much more difficult to build reputations than in 
markets for experience goods (trust games can be thought of stylized representations of such 
markets). Thus, patients find it very hard to learn whether they received the treatment they 
needed from a particular physician (i.e. whether trust was honored or not). Second, our 
parameter choices imply that the incentives are stacked against consulting the physician: the 
payoff from receiving the correct treatment is only one point higher than the outside option, 
whereas being overtreated reduces the payoff by seven points (see figure 2).  
As pointed out in the description of the equilibria, physicians have an incentive to provide 
the severe treatment whenever they get a chance. However, we expect the overtreatment rate 
to be below 1 as we know from many previous experiments (e.g. Bohnet et al. 2005, Riedl and 
                                                     
20  The baseline game is a dynamic game with incomplete information. In a strict sense, the appropriate 
equilibrium concept is the Perfect Bayesian equilibrium. However, as there is no action of another player 
involved when patients form their beliefs (about their own unknown type), the belief has to be equal to the 
underlying probability distribution. Moreover, the physician is informed about the patient’s type when deciding 
on the treatment, so applying backward induction is appropriate to solve the game. 
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Tyran 2005) that many subjects tend to honor trust (i.e. reciprocate) even when this is not in 
their own monetary interest. 
3.2 Predictions in the insurance condition 
In the conditions with insurance, the (additional) cost of an unnecessary severe treatment is 
socialized, i.e. shared among all patients in the market. Intuitively, this means that patients have 
little incentive to avoid being overtreated. In INS, this creates incentives for patients to consult 
the physician they have been randomly matched with irrespective of whether she is in good 
standing (moral hazard). In INS-COMP, insurance undermines incentives to be choosy in whom 
to consult compared to the case without insurance (COMP). Thus, in both cases, insurance is 
expected to create incentives for consulting. The unique equilibrium in which patients consult 
the assigned physician and physicians always provide a severe treatment is formally derived in 
appendix E. 
Behaviorally, insurance is expected to increase the consulting rate and the overtreatment 
rate but not to the level predicted by standard theory (i.e. we expect consulting and 
overtreatment to be higher in INS compared to BASE and in INS-COMP compared to COMP, 
respectively). Note that in the conditions with insurance, a patient’s decision of whether to 
consult a physician (given he expects to be overtreated) is equivalent to the choice faced in a 
public good game: The individual benefit of receiving the treatment exceeds the disadvantage 
of having to pay a higher insurance premium. As a group however, patients would be better off 
if no patient consulted a physician (i.e. individual rationality contradicts collective rationality). 
The experimental literature on linear public good games (for an overview, see Ledyard 1995) 
shows that subjects contribute (to some extent) to a public good even though it is not 
individually rational. For this reason we do not expect insurance to increase the consulting rate 
to the level predicted by standard theory.  
3.3 Predictions for conditions with competition 
In the treatment conditions allowing for competition, patients can freely choose between the 
physicians in their market. As in the conditions without competition, the history table provides 
each patient with a summary of what kind of treatment he himself got (but not the severity of 
the problem). But in addition to what patients in treatments without competition see, patients 
in COMP and INS-COMP also get information about how many patients visited each physician, 
i.e. the market shares of each physician, but not what treatment the other patients got. This 
additional information becomes increasingly useful in gauging the trustworthiness of physicians 
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as the experiment progresses. When the proportion of severe treatments provided by a 
particular physician deviates too strongly from the base rate (1/3) of a severe treatment, 
patients can estimate that this physician was likely to have overtreated. Physicians now have a 
reputational incentive to provide the required treatment if patients systematically choose to 
consult the physician with the best odds to have treated the patient correctly. This reputation 
mechanism is amplified by the fact that patients can observe other patients’ past consulting 
choices. Patients can now choose physicians with whom other patients apparently have made 
good experiences (indicated by a high number of visitors). 
While information about market shares has some potential to create reputational 
incentives, these incentives build up only slowly with experience and are likely to remain weak 
even towards the end of the game because the inference problem is difficult with a noisy signal. 
When a patient gets a severe treatment, he is uncertain whether this treatment was 
appropriate or excessive.21 Another limit to the power of reputational incentives is the fact that 
patients can only recall their own experience with a given physician (if they consulted her at all) 
but not how this physician treated other patients in the market. A patient can therefore only 
slowly benefit from other patients’ experiences by shunning physicians with a decreasing 
market share. Despite these two limitations of patient’s possibility to react to physicians’ 
behavior, we expect competition to have a positive effect on the consulting and a negative 
effect on the overtreatment rate (increase of consulting and decrease of overtreatment rate 
from BASE to COMP). The same considerations apply in the presence of the insurance; hence 
we expect the consulting rate to increase and the overtreatment rate to decrease from INS to 
INS-COMP.  
In summary, we expect competition (i.e. the free choice of physicians) to reduce 
overtreatment and thus to increase consulting. That is, we expect the consulting rate to be 
higher and the overtreatment rate to be lower in COMP than in BASE, and we expect the same 
to hold in INS-COMP compared to INS.  
4. Results 
We first present descriptive statistics and discuss aggregated treatment effects. We continue 
with the analysis of the additional control treatments and a regression analysis. Finally, we 
                                                     
21  After 10 (15, 20, 30) interactions with a specific physician, a patient needs to receive a severe treatment in at 
least 7 (9, 11 15) out of these interactions in order to be able to reject the null hypothesis that the physician is 
always providing the appropriate treatment at the 5 percent level. It is hence rather difficult for patients to 
detect overtreatment. 
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present additional health economic measures and discuss cost-effectiveness of alternative 
institutions in terms of public health status vs. total expenditures, and close with a discussion of 
inequality amongst patients. In appendix G we describe behavior over time, and in appendix H 
we discuss whether overtreatment is related to physicians’ market shares. 
4.1 Descriptive statistics 
Table 2 shows the consulting rate (i.e. the share of consulting patients) and the overtreatment 
rate (i.e. the share of consulted physicians who provide a severe treatment when the problem is 
mild22) averaged across markets and periods in lines (1) and (2). In BASE, both of these shares 
are at intermediate levels: 40.7 percent of patients consult and only 26.3 percent of consulting 
patients are being overtreated. Both of these findings are remarkable considering the 
predictions of standard theory since consulting (i.e. trusting the physician) is ill-advised and the 
incentives for overtreatment are quite strong. This combination results in a fairly high efficiency 
rate (realized earnings relative to potential payoff, see line 3). 
Table 2: Aggregate results  
 BASE COMP INS INS-COMP 
(1) consulting rate 40.7 54.7 55.3 83.1 
(2) overtreatment rate 26.3 7.2 70.9 34.2 
(3) efficiency rate 61.2 70.5 71.5 89.5 
(4) correct treatment rate (CTR) 29.6 49.7 16.2 54.9 
(5) average earnings physicians 9.1 11.5 14.4 19.1 
(6) average earnings patients 6.8 7.2 5.7 6.4 
Notes: The table shows averages over all 30 periods and 7 markets in the main treatments. The rates in the 
first four lines are indicated in percent: (1) is the share of consulting patients, (2) is the share of consulted 
physicians who give severe treatment when the problem is mild, where the average rate (2) is weighted by the 
number of consultations per session and period. (3) is the sum of actual earnings over the sum of potential 
earnings, (4) is the share of all interactions when appropriate treatment is provided. Average earnings in (5) 
and (6) are indicated in points.  
 
                                                     
22  In the remainder of the paper, we present all overtreatment rates conditional on patients having a mild 
problem (i.e. excluding periods with a severe problem). See appendix C for overtreatment rates including 
periods with a severe problem which tends to depress the overtreatment rates.  
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According to the definition of efficiency in (3), overtreatment implies no efficiency 
loss (overtreatment is a pure redistribution from patients to physicians in our design). 
According to this measure even a (socially undesirable) situation in which all patients 
consult and all physicians over-treat is considered efficient. The “correct treatment rate” 
(CTR) is an alternative measure of efficiency that does not have this property. The CTR is 
the share of interactions in which the patient gets the treatment he needs. Thus, both the 
consulting rate and the overtreatment rate determine the CTR.23 As in the calculation of 
the overtreatment rate, we consider only periods with a mild problem (for the CTR 
including periods with a severe problem, see appendix C).24 The remaining lines (5) and (6) 
show earnings of physicians and patients, respectively. 
4.2 The impact of insurance and competition  
Table 2 shows that insurance induces more consulting but also boosts overtreatment, 
compared to the baseline condition, as expected.25 The overtreatment rate almost triples (from 
26.3 to 70.9 percent) and the correct treatment rate therefore suffers (falls from 29.6 to 16.2 
percent), but the consulting rate still increases from 40.7 to 55.3 percent. When using the 
rather conservative Wilcoxon-Mann-Whitney tests26 (which treat the average over all periods in 
market as one independent observation) to assess the significance of these effects, we find that 
the effect of insurance on the overtreatment rate is highly significant while the effect on 
consulting is not (see table 3). This lack of significance is perhaps due to the high degree of 
heterogeneity of the consulting rate across markets in BASE (3 markets have rates around 15 
percent, two around 65 percent, see figure D1 in the appendix). It is mostly physicians who 
benefit from insurance (their incomes increase by more than 50 percent, from 9.1 in BASE to 
                                                     
23  The reason that the CTR is not exactly equal to consulting rate x (1- overtreatment rate) in table 2 is that the 
trust rate shown in table 2 is the overall consulting rate (share of patients consulting) rather than the trust rate 
conditional on the problem being mild. The conditional consulting rate is shown in appendix C.  
24  Equivalently, the CTR including periods with severe problem can be calculated using the trust and 
overtreatment rates including periods with a severe problem (a comparison of all measures presented in table 2 
both including and excluding periods with a severe problem can be found in appendix C).  
25  The finding that insurance boosts demand is indeed unsurprising to an economist. Cutler and Zeckhauser (2000) 
note in the Handbook of Health Economics: “essentially all economists accept that traditional health insurance 
leads to moderate moral hazard in demand.”  
26  The WMW test assumes that the two distributions being tested are identical except for a shift. As this 
assumption might be violated with experimental data we additionally perform a robust rank order test (see 
Fligner and Policello 1981) that assumes neither equal variances, nor equal shape of the distributions. The level 
of significance using the robust rank order test is for no comparison lower, and in some cases higher, than with 
the WMW test. For the detailed results see appendix C, table C3.  
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14.4 points in INS on average, and this effect is highly significant, see table 3). Patients suffer as 
they rush to consult while being overtreated at much higher rates than without insurance (their 
incomes drop significantly, from 6.8 to 5.7 points. Recall that the costs of being overtreated 
dominate the benefits of being treated at all). However, the effects of insurance on the CTR are 
not significant according to the WMW test. 
Table 3: Wilcoxon-Mann-Whitney (WMW) test – empirical z-values 
 Impact of competition   Impact of insurance 
 Without insurance   
With  
insurance  
 
Without 
competition 
With  
competition 
 BASE vs. COMP  INS vs.  INS-COMP 
 BASE vs. INS COMP vs.  INS-COMP 
(1) consulting rate  -1.28  -2.62 ***  
 
-1.09  -2.75 ***  
(2) overtreatment rate   3.00 ***   2.36 **  
 
-3.13 ***  -3.07 ***  
(3) efficiency rate  -1.34  -2.62 ***  
 
-1.09  -2.75 ***  
(4) correct treatment rate (CTR)  -1.60  -2.36 **  
 
 0.83  -0.58  
(5) average earnings physician  -1.09  -2.49 **  
 
-1.98 **  -2.88 ***  
(6) average earnings patients  -1.60  -1.47  
 
 2.88 ***    1.73 *  
Notes: see table 2 for explanations of variables. Positive numbers indicate that the value of the variable is larger 
in the treatment condition named first, and vice versa for negative values. * p ≤ 0.1;   ** p ≤ 0.05;  *** p ≤ 0.01 
 
Competition in the guise of “informed choice” has largely beneficial effects, as expected: 
It reduces overtreatment and increases consulting. The effects are rather strong. 27  
Overtreatment is cut by about half with insurance (falls from 70.9 to 34.2 percent) and by about 
two thirds without insurance (from 26.3 to 7.2 percent). Both of these effects are statistically 
highly significant according to the WMW test, see table 3. Competition increases the consulting 
rate by about a third absent insurance and by about 50 percent with insurance. The effect of 
                                                     
27  Recall that we discuss the effects of competition in the guise of “informed choice” in this section, meaning that 
the comparison of BASE vs. COMP and of INS vs. INS-COMP show the effect of allowing patients to choose a 
physician and of being informed about market shares (i.e. how many patients consult with each physician). The 
effects of physician choice absent information on market shares (i.e. the effect of “pure competition”) and of 
providing information about market shares are discussed in section 4.3. 
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competition is highly significant with insurance (i.e. INS vs. INS-COMP) but not without 
insurance (i.e. BASE vs. COMP) according to a conservative Wilcoxon-Mann-Whitney test. 
Perhaps surprisingly, competition does not have much of an effect on patients’ earnings 
(no significant differences).28 The reason is that the payoff difference from not consulting vs. 
being treated correctly is rather small (one point payoff difference for a patient). Perhaps even 
more surprisingly, physicians tend to benefit from competition (the difference is significant for 
the conditions with insurance). The reason is that the increase in profit from the increase in the 
consulting rate more than compensates the loss in physicians’ profit from the decrease of the 
overtreatment rate. Regarding efficiency, competition increases both the efficiency rate and the 
correct treatment rate; the differences are again only significant for the conditions with 
insurance. The finding that the beneficial effects of competition (in particular on the consulting 
rate and on the efficiency rate) are stronger with insurance is somewhat surprising. A closer 
look at the data suggests that this is due to the high variation of the consulting rate across 
markets in the baseline condition: the average consulting rate is below 20% in three markets 
while it is higher than 60% in two markets (see appendix D). Therefore, it is likely that the lack of 
statistical significance comparing the baseline and the condition with competition is due to the 
rather small number of independent observations per condition. 
The effects of insurance given competition are strong, in line with our expectations and 
significant in all cases (with the exception of the CRT). In particular, insurance induces moral 
hazard on the side of patients (the consulting rate increases from 54.7 to 83.1 percent), and 
boosts overtreatment by almost factor 5 (from 7.2 to 34.2 percent). Insurance is again (as in the 
case without competition) to the benefit of physicians (their incomes increase from 11.5 to 
19.1) while patients’ incomes even fall (from 7.2 to 6.4 points, weakly significant). 
4.3 The impact of market shares 
As pointed before, the comparison of the main treatments BASE vs. COMP and INS vs. INS-
COMP measures the effect of introducing “informed choice” in the sense that we not only 
enable patient to choose which physician they want to consult (if any) but at the same time also 
provide the patients (and the physicians) with information about how popular physicians are by 
making market shares observable. It is possible that such informed competition is more 
                                                     
28  Nonetheless, COMP is the only condition in which patients benefit from consulting a physician. In BASE, the 
expected payoff of consulting (given the observed physician behavior) is lower than the expected payoff of not 
consulting. In the conditions with insurance, an individual patient should always consult even if he expects to be 
overtreated (due to the incentives of the insurance, see section 3.2). On the group level, however, the group of 
all patients would be better off if they refrained from consulting (given the behavior of an average physician). 
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powerful than “pure competition” without information about market shares as such 
information might channel patients to popular physicians who, in turn, have sharper incentives 
to earn popularity by providing adequate treatments. One might therefore wonder what the 
effects of “pure” competition in isolation are. Conversely, one might wonder what the effects of 
providing information are in the absence of competition.  
To investigate this issue, we implement two control treatments called COMP_nms and 
INS-COMP_nms (where “nms” stands for “no market shares") serving to decompose the total 
effect of “informed choice” into an effect of “pure competition” and an effect of “market 
information”. Note that a plausible result of such a decomposition is that none of the two 
effects turns out significant despite the composite effect being significant. Such a finding would 
simply point to interaction effects.  
Table 4: Descriptive results for the control treatments 
 Conditions without insurance 
Conditions with  
Insurance 
 BASE COMP_nms COMP INS 
INS-
COMP_
nms 
INS-
COMP 
(1) consulting rate 40.7 42.2 54.7 55.3 79.8 83.1 
(2) overtreatment rate 26.3 20.7 7.2 70.9 44.4 34.2 
(3) efficiency rate 61.2 61.8 70.5 71.5 87.7 89.5 
(4) correct treatment rate (CTR) 29.6 34.1 49.7 16.2 43.8 54.9 
(5) average earnings physicians 9.1 9.2 11.5 14.4 19.1 19.1 
(6) average earnings patients 6.8 6.9 7.2 5.7 6.1 6.4 
no. markets ; no. subjects  7 ; 56  7 ; 56 7 ; 56 7 ; 56 7 ; 56 7 ; 56 
Notes: Table shows averages over all 30 periods and 7 markets per treatment. (1) is the share of patients 
who consult a physician, (2) is the share of consulted physicians who give severe treatment when the 
problem is mild, where the average (2) is weighted by the number of consultations per session and period. 
(3) is the sum of actual earnings over sum of potential earnings, (4) is the share of all interactions with 
needed treatment provided. Average earnings in (5) and (6) are indicated in points.  
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The control treatments COMP_nms and INS-COMP_nms are identical to the conditions 
COMP and INS-COMP, respectively, except for the fact that physicians’ market shares are not 
displayed in the history window of their screens (neither for the patients nor for the physicians). 
Everything else (in particular the matching procedure) is identical to the conditions with 
competition.  
The follow-up was run at the same laboratory (at the University of Copenhagen) using the 
same software, subject pool and recruiting system, instructions and procedures as for the main 
treatments. We made sure that each subject participated in one session only. Overall, 112 
subjects participated in seven markets per control treatment. They earned 215.1 DKK each on 
average which is not significantly different from average earnings in the main treatment (p = 
0.631, Wilcoxon-Mann-Whitney tests).  
Table 4 shows that the outcomes in the control treatments are without exception 
between the outcomes in the respective main treatments. That is, every single out of 12 
measures for the treatments with competition but without information about market shares is 
between the respective treatment without such information and the respective treatment with 
competition. This is a comforting finding, indicating that the results seem fairly robust and can 
be nicely replicated. Inspection of the values reveals that the values for COMP_nms are closer 
to BASE than to COMP, and that INS-COMP_nms is closer to INS-COMP. Eyeballing thus 
indicates that the effect of “pure competition” was stronger in the presence than in the 
absence of insurance. 
Table 5 provides statistical tests for differences between the controls and the respective 
main treatments that span the total effect of “informed choice”. With one exception, we find 
that market shares have no independent effect (in addition to the effect of competition) as 
there are no significant differences between the main treatments involving such information 
and the respective control (see right half of the table). However, the one exception is 
somewhat surprising because it indicates (together with the insignificant effect of BASE vs. 
COMP_nms in line 2) that the total effect of “informed choice” on overtreatment in BASE vs. 
COMP was mainly driven by information and only secondarily, if at all, by “pure competition”. 
Yet, from the right half of the table it becomes clear that this is somewhat of an outlier result as 
all other (11 out of 12) tests indicate non-significance of information. We believe the outlier has 
to do with the large degree of heterogeneity of markets in BASE and the relatively small 
number of independent observations (see figure D1).  
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Table 5: Wilcoxon-Mann-Whitney (WMW) test – empirical z-values 
 
Effect of  
pure competition  
(no market shares) 
 Effect of information 
about market shares  
(in add. to competition) 
 
(1) 
Without 
insurance   
(2) 
With  
insurance  
 (3) 
Without 
insurance   
(4) 
With  
insurance 
 BASE vs. COMP_nms  
INS vs.  
INS-COMP_nms 
 COMP_nms vs. 
COMP 
INS-COMP_nms 
vs. INS-COMP 
(1) consulting rate  -1.19  -2.95 ***   -1.21  -1.41  
(2) overtreatment rate   0.06   2.36 **  
 
 1.98 **   0.07  
(3) efficiency rate  -0.45 -3.00 ***  
 
-1.09  -1.34  
(4) correct treatment rate (CTR)  -0.19 -2.75 ***  
 
-1.09  -1.09  
(5) average earnings physician  -0.06  -2.36 **  
 
-1.09  -0.19  
(6) average earnings patients  -0.32  -1.34  
 
-1.09  -1.09  
Notes: see table 2 for explanations of variables. Positive numbers indicate that the value of the variable is larger 
in the treatment condition named first, and vice versa for negative values. * p ≤ 0.1;   ** p ≤ 0.05;  *** p ≤ 0.01 
Testing also reveals no evidence of an independent effect of “pure competition” absent 
insurance (see column 1). But we do find strong evidence of an independent effect of pure 
competition when insurance is present (see column 2). In fact, 5 out of 6 tests indicate a 
significant difference (at the 5 percent level or better according to a WMW-test) between 
outcomes with and without competition when patients are shielded from bearing the full cost 
of overtreatment (and do not get information about market shares). We summarize the 
discussion above as follows. In our main treatments, we find strong effects of insurance, and 
we also find strong effects of competition in the presence, but not in the absence, of insurance 
(see table 3). However, this effect of competition measures the joint effect of providing 
information about market shares and of allowing patients to choose physicians, i.e. it measures 
the effect of what we call “informed choice”. We have therefore run two control treatments to 
determine whether that effect is mainly due to the ability to choose as such (i.e. “pure 
competition” effect) or to the additional information provided. The results in table 5 show that 
matters are not totally unambiguous in the condition absent insurance (none of the two effect 
seems to be dominant except for overtreatment which seems to be driven by information 
provision), but the evidence is clear and unambiguous in the case with insurance. Here we find 
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that the strong effect of “informed competition” was mainly due to “pure competition” and 
there is no evidence of an independent effect of providing “information” as such. This result is 
comforting because it upholds our interpretations that differences between the main 
treatments that do or do not involve competition mainly reflect the effect of competition 
(“pure and simple”).  
4.4 Regression analysis 
Table 6 presents the results of a panel probit regression. The second line shows that insurance 
unambiguously increases both consulting and overtreatment. With respect to competition, we 
have to decompose the effect of “informed choice” into pure competition and the observability 
of market shares. For consulting, the regression results indicate that the overall positive effect 
of competition is to a greater extent driven by free choice than by the observability of market 
shares (compare line 1 and line 3). For overtreatment, however, pure competition turns out to 
be insignificant, in contrast to the observability of market shares (the impact of market shares is 
conditional on the presence of pure competition as we do not conduct a control treatment 
without free choice but with market shares.  
Line 4 shows that time trends are quantitatively weak and tend to be negative for 
consulting and positive for overtreatment. Line 5 shows that a patient is less likely to consult if 
he got severe treatments more often than expected (i.e. the dummy Sev_high takes a value of 1 
if a patient got severe treatment in more than a third of the cases). Line 6 shows that physicians 
are more likely to overtreat when the benefits of doing so are high, i.e. when many patients 
choose to consult with her. All of these effects are robust to the inclusion of gender and field of 
study as controls. 
Lines 7 to 12 show interaction effects. For example, column (C) shows that receiving 
severe treatments beyond expectations (i.e. when Sev_high = 1) discourages patients from 
consulting when competition prevails but this effect is weak when insurance spreads the cost of 
severe treatments to the entire group (-0.18 is more than compensated by 0.26). Line 11 in (C) 
shows that there are positive interaction effects between insurance and pure competition 
concerning consultation: adding competition to the conditions with insurance increases the 
demand for consultation as does adding insurance to the conditions with competition. 
However, we find no such interaction effects for overtreatment, see line 11 in col. (F). Finally, 
we find that physicians who are consulted by more than one patient are more prone to 
overtreat (line 6, col. F), but that this effect is mitigated by competition (see line 9. Appendix H 
provides more details on this relation). 
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Table 6: Average marginal effects (panel probit regression)  
 Dep. variable Consulting Overtreatment 
      (A)      (B)     (C)     (D)     (E)     (F) 
1 COMP  0.21***  0.23***  0.23*** -0.10 -0.11 -0.14 
2 INS  0.24***  0.24***  0.24***  0.39***  0.35***  0.35*** 
3 Obs_shares  0.05  0.03  0.04 -0.24*** -0.21*** -0.20** 
4 Period -0.00*** -0.00*** -0.00***  0.00**  0.00**  0.00** 
5 Sev_high -0.20*** -0.20*** -0.18*** - - - 
6 #Pat_high - - - 0.08*** 0.07*** 0.06** 
7 COMP x Sev_high - - -0.03 - - - 
8 INS x Sev_high - -  0.26*** - - - 
9 COMP x #Pat_high - - - - - -0.15*** 
10 INS x #Pat_high - - - - - -0.00 
11 COMP x INS - -  0.17** - - -0.14 
12 Obs_shares x INS   -0.01   -0.00 
 Controls No Yes Yes No Yes Yes 
 No. of obs. 5346 5346 5346 1632 1632 1632 
 AIC 0.958 0.958 0.957 0.914 0.910 0.909 
Notes: Table shows average marginal effects from a panel probit regression (see appendix C, table C4 for 
regression coefficients). Dependent variables are dummies which indicate in (A) to (C) whether or not a 
patient consults a physician, and in (D) to (F) whether or not a physician overtreats conditional on being 
consulted. COMP, INS and Obs_shares are dummies indicating the treatment variations. COMP 
indicates whether patients can choose their physician (i.e. equals 1 for COMP, COMP_nms, INS-COMP 
and INS-COMP_nms), INS denotes the presence of the insurance, and Obs_shares indicates whether 
market shares are observable (i.e. equals 1 for COMP and INS-COMP). Sev_high = 1 when the rate of 
severe treatments a patient got so far exceeds its mathematical expectation, i.e. 1/3, and = 0 otherwise. 
#Pat_high = 1 if physician was consulted by more than one patient, and = 0 otherwise. Controls “Yes” 
indicates that the regression includes gender and field of study.  
4.5 Measures reflecting public health  
This section presents two additional measures serving to evaluate the results of our experiment 
taking a perspective of public health.  
Figure 5 illustrates the cost-effectiveness of alternative institutional arrangements. The 
figure compares the overall expenditures of the laboratory “healthcare system” under study 
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with the “average health status” in the population.29 We define the total health expenditures as 
the average transfer (in points) from the patients to physicians. For a given patient, these 
expenditures are zero if he does not consult a physician, they are 𝑝(𝑚) = 15 if he receives a 
mild treatment and 𝑝(𝑠) = 22 for a severe treatment. We measure the state of public health by 
the share of patients whose problem was solved. Note that these two measures are by 
definition positively associated (by design, a patient’s problem can only be solved if a treatment 
has been provided – and treatments are, again by design, costly). The dashed line indicates the 
expenditures that are required to reach a particular level of public health assuming there is no 
overtreatment. 
Figure 5 shows that INS and COMP produce a similar level of public health, but INS does 
so at a cost that is almost 20 percent higher. These excess costs result from the (two-sided) 
moral hazard effects the insurance coverage induces. Thus, the institution of free choice of 
physician dominates the institution of insurance in terms of the trade-off shown here if one has 
to choose between the two.  
Figure 5: Public health status vs. total expenditures 
 
                                                     
29  We would like to emphasize that the present analysis refers to the context of our laboratory experiment and 
that the terms used in this section should not suggest that we are referring to the health care sector in any 
particular country. The goal of our study is not to give policy recommendations based on our laboratory 
experiment, but to study human behavior in this particular, rather abstract setting. Of course, the insights of our 
study have to be corroborated and refined in a field setting before further conclusions should be drawn. 
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The highest level of public health is achieved in INS-COMP. According to the measure 
used here, it is about twice the level in BASE. This impressive performance, however, is also 
associated with the highest total expenditure. The figure thus illustrates the trade-off a society 
may face when making institutional choices in health care: insurance increases the level of 
public health substantially by making sure that patients with a problem indeed consult a 
physician. But insurance at the same time also boost expenditures: the first reason is exactly 
because the patients want to be treated, the second is because physicians overtreat much 
more knowing that patients do not have to bear the full cost of overtreatment. Furthermore, 
the horizontal distance to the dashed line is higher in the conditions with insurance – indicating 
that the same level could be reached at a lower level of total expenditures. 
Figure 6 paints a somewhat more favorable picture of the effects of insurance. While it is 
true that insurance invites moral hazard from both sides of the market, it also provides the 
benefit of a more even distribution of (material) welfare among patients. Insurance means that 
the risk of having to bear the cost of severe treatments is borne by society at large rather than 
by the individual who has been unfortunate enough to suffer from a severe problem.  
Figure 6: The upside of insurance: reduced uncertainty (inequality) 
 
The figure shows that inequality of incomes among patients (measured by the variance of 
incomes) is lowest when patients are covered by medical insurance and much higher in the 
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conditions without insurance. However, this higher degree of safety (or equality) among 
patients comes at a price, as patient wealth is also lower with insurance than without. 
5. Concluding remarks 
We have used the methods of experimental economics to study how competition and insurance 
shape outcomes in the interaction between patient and physician, with a particular focus on 
patient overtreatment. The provision of a medical treatment is a typical example of a credence 
good, and we therefore investigate a stylized market for credence goods. 
We find that competition in the guise of giving patients free choice of physician exerts 
pressure on physicians not to overtreat patients (because overtreating physicians are shunned 
to some extent). This, in turn, seems to reassure patients and induces additional patients to 
consult a physician. Additional consultations tend to increase efficiency as more health 
problems are solved, and solved properly. As expected, we find that insurance induces moral 
hazard on both sides of the market. With insurance, more patients consult a physician as the 
additional cost of treatment (including overtreatment) is not borne by the consulting patient 
but by all patients collectively. The upside of insurance is that it inspires confidence in patients 
and distributes the cost more evenly among patients. The downside is that physicians respond 
to more careless demand for medical treatments by overtreating patients more often.  
The interaction effects between the institutions are particularly interesting and pro-
nounced. Competition mitigates much of the adverse effects of insurance. Overtreatment rates 
are not much higher in INS-COMP than in BASE (34 vs. 26 percent, p = 0.749 WMW-test). At the 
same time, the beneficial effect of insurance on inspiring confidence (or trust) in the system is 
boosted (the consulting rate is much higher, at 83 percent, than in either COMP or INS, both at 
about 55 percent). As a result, efficiency is high and patients are fairly likely to get the 
treatment they need. However, physicians reap more of the benefits of having these 
institutions (their earnings are about three times as high as patients’ earnings with insurance, 
and this is also true in INS-COMP). 
From a public health perspective, we identify a trade-off between the average health 
status in the population and the cost of the healthcare system. We observe the highest level of 
public health in the condition with insurance and free choice of physician but costs are high and 
overtreatment is prevalent. It does not seem possible (at least within our simple framework) to 
reduce costs or the level of overtreatment without decreasing the level of public health at the 
same time. Comparing the effectiveness of insurance and competition, we find that the level of 
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public health is comparable, but overall expenditures are lower with competition. On the other 
hand, insurance reduces inequality amongst the group of patients.  
We conclude that competition in the guise of free choice of physician has unambiguously 
beneficial effects in our setting. Informed competition increases the level of public health and 
decreases overtreatment at the same time. Even though the increased level of public health 
leads to higher total expenditures, the total expenditures are not as high as they could be – 
because competition provides incentives to keep overtreatment reasonably low. Of course, 
extrapolation to health care policies in the field is difficult. Here are three reasons. First, 
competition is not the only mechanism that can reduce overtreatment, and quite possibly it is 
not the best that can be thought of. For instance, Brosig-Koch et al. (2014) find that 
overprovision is significantly lower in a mixed-fee-for-service remuneration system (where the 
fee-for-service component is complemented by a lump-sum component) compared to a pure 
fee-for-service system. One would need a comparative evaluation of competition and mixed-
fee-for-remuneration or other potential measures to be on safer ground for policy advice. 
Second, there are distinct differences between the anonymous interactions in an abstract 
laboratory setting and the interactions of patients and physicians in the field where personal 
interaction often plays a role. We think it would be interesting for follow-up research to 
investigate the effects of the institutions studied here in controlled environments that are 
richer in context. Third, professional norms are also likely to play an important role for the 
degree to which physicians engage in opportunistic behavior. Kesternich et al. (2015) for 
instance show (in a controlled laboratory-like internet experiment) that medical students are 
more likely to sacrifice parts of their own income for a patient’s benefit if they are primed for 
professional norms (in the context of the Hippocratic Oath). 
An advantage of our experimental design is that these factors are held constant across 
conditions. We can hence interpret differences across conditions (instead of absolute levels) 
and describe the effects of the institutions under investigation. We are able to identify causal 
mechanisms by implementing ceteris paribus variations which are difficult if not impossible to 
implement in a field setting. Furthermore, the error-free observability of outcomes – in 
particular regarding overtreatment – is very difficult to achieve in the field.    
Last but not least, it is important to note that our results can only be interpreted in the context 
of healthcare systems in which physicians benefit from providing a high level of medical care 
(i.e. in a fee-for-service remuneration system). In healthcare systems where physicians receive 
a fixed premium per patient (i.e. in a capitation remuneration system), patients tend to suffer 
from undertreatment rather than overtreatment – a phenomenon we abstract from in our 
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experiment. Our results tentatively suggest that free choice of physician might also be a good 
instrument to mitigate undertreatment in a capitation remuneration system. A fruitful alley for 
future research, we think, is to determine whether this is in fact the case.    
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Appendix A – Instructions for treatment INS-COMP 
(Instructions for the other treatments are available from the authors on request) 
 
Welcome to the experiment. 
 
Please read these instructions carefully. Do not speak to the other participants and keep quiet 
during the entire experiment. In case you have a question please raise your hand. We will then 
come to you. 
 
At the beginning of the experiment you are randomly assigned to groups of 8 participants – out 
of which 5 will be Clients and 3 will be Advisers. You will be informed whether you are a 
Client or an Adviser at the beginning of the experiment. During the experiment you solely 
interact with the participants of your group. 
 
In this experiment you can earn money. The show-up fee amounts to 75 DKr for both Clients and 
Advisers. During the experiment we do not talk about DKr, but about points. You can earn 
additional points according to the choices you make. These points will be converted into Danish 
Crowns (DKr) and paid to you in cash at the end of the experiment according to the following 
exchange rate: 
2 points = 1 DKr 
 
How much you earn depends on your decisions and on the decisions of other participants in your 
group. All participants receive the same instructions. All decisions are made anonymously. That 
is, no other participant will get to know your name or your income.  
 
General Description 
 
You are in a group with 7 other participants. At the beginning of the experiment all participants 
are randomly assigned to one of two roles (Client or Adviser). You will be informed about your 
role at the beginning of the experiment. There are five Clients and three Advisers (A1, A2, and 
A3). All participants keep their role and the number assigned to them throughout the experiment.  
 
The experiment consists of 30 periods. In each period, the Clients have a new problem. All the 
Clients have the same problem. In each period the computer randomly determines whether the 
problem is severe or mild. The problem is severe in one third of the cases, and in two thirds of 
the cases the problem is mild:  
 
 1/3 of the cases the problem is severe 
 2/3 of the cases the problem is mild 
 
In each period, the Clients have to decide if they want to consult an Adviser or not. If they want 
to consult, they have to choose which Adviser to consult. The Clients do not know whether their 
problem is severe or mild. The Advisors, however, do know the severity of the clients’ 
problem. If a Client consults an Adviser, the Adviser provides a treatment that solves the 
problem. If a Client decides not to consult an Adviser, the problem will not be solved. Hence, if a 
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Client decides to consult an Adviser, the Client’s problem will always be solved, but he will not 
learn the true severity of the problem. As a result, the Adviser may provide the severe treatment, 
even though the true severity of the problem is only mild. 
 
After each period, the participants will be informed of their income in this period and of their 
total income earned so far. We explain how incomes are calculated below. 
 
Task of a Client 
At the beginning of each period, each Client has to decide whether or not to consult an Adviser. 
This means that a Client has to decide whether he wants to consult A1, A2, A3, or none of them. 
 
At the beginning of a period, the computer randomly determines the true severity of the problem. 
All Advisers are informed about the true severity of the problem, but the Clients do not know the 
true severity of the problem. If a Client chooses not to let an Adviser solve the problem, he will 
learn the true severity of the problem at the end of the period. If he chooses to consult an 
Adviser, he will not learn the true severity of the problem, but is only informed about the 
treatment provided by the Adviser.  
 
Task of an Adviser 
The Advisers know the true severity of the Clients’ problems regardless of whether or not any of 
the Clients chose to consult him. As there are a total of 5 Clients, an Advisor can be consulted by 
up to 5 Clients in one period. An Adviser only learns the number of Clients who chose to consult 
him, but he will not learn the identity of those who chose to consult him. If an Adviser is 
consulted by any of the Clients, the Adviser has to provide the same treatment to all Clients. If 
the problem is severe he has to provide the severe treatment. If the problem is mild, he can 
provide either the mild treatment or the severe treatment. 
 
Income 
The Income Table (see separate sheet) shows the incomes for both an Adviser and a Client for all 
possible cases. 
 
The Income earned by a Client: 
If a Client chooses not to consult an Adviser, he gets no treatment. In this case, his income 
depends on the severity of his problem and on the total number of severe treatments in the group. 
If his problem is severe he earns 7*
5
#2 treatmentssevereof ⋅⋅⋅−  points (where “# of severe 
treatments” is short for “number of severe treatments”) or 0 if the amount in this formula 
becomes negative (Nobody can never make a loss in this experiment.). If, on the other hand, his 
problem is mild he earns 7*
5
#9 treatmentssevereof ⋅⋅⋅−  points. See first line in the Income 
Table. 
If a Client decides to consult an Adviser, his income will not depend on the treatment provided 
by the Adviser, but solely on the total number of severe treatments in the group. If the Adviser 
decides to provide the mild or the severe treatment, the client earns 
7*
5
#10 treatmentssevereof ⋅⋅⋅−  points.  
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Notice, however, that while the Advisor will always provide the severe treatment when the 
problem is severe, he can decide to provide either the severe treatment or the mild treatment 
when the problem is mild. Clients who consult an Advisor will always learn if they received the 
mild or the severe treatment. Moreover, all Clients will observe the total number of severe 
treatments in the group (Advisor’s don’t). 
 
The income earned by an Advisor: 
Remember that it is possible for an Adviser to be chosen by several Clients. This means that the 
income earned by an Adviser from the interaction with one Client, as shown in the Income 
Table, should be multiplied by the number of clients that have chosen to consult him.  
 
Examples:  
 
Suppose the true severity of the problem is mild, an Adviser has been chosen by 4 Clients, and 
the Adviser chooses to provide the severe treatment. In this case the Adviser’s income is (4*17) 
= 68. The fifth Client does not consult an Advisor.  
The income of the 4 Clients who sought treatment is 10 – (4/5)*7 = 4.4 while the income of the 
fifth Client who did not seek treatment is 9 – (4/5)*7 = 3.4. 
 
Suppose the problem is mild and two Clients have decided to consult an Advisor. We see from 
the Income Table that the income earned by the Adviser from one Client is 10 points if he 
provides the mild treatment while it is 17 points if he provides the severe treatment. As two 
Clients decided to consult him, his total income in this period is (2*10) = 20 points if he provides 
the mild treatment while it is (2*17) = 34 points if he provides the severe treatment.  
Only one other Client consults a different Advisor and gets a severe treatment.  
In the first case where the first two Clients get a mild treatment all three Clients who sought 
treatment earn 10 – (1/5)*7 = 8.6 each while the income of those who didn’t seek treatment is 9 – 
(1/5)*7 = 7.6. In the second case with severe treatment for the first two Clients all three Clients 
who sought treatment earn 10 – (3/5)*7 = 5.8 each while the income of those who didn’t seek 
treatment is 9 – (3/5)*7 = 4.8. 
If the problem was severe all Clients who sought treatment would earn 10 – (3/5)*7 = 5.8 and 
the Clients who didn’t seek treatment would earn 0 (because 2-(3/5)*7=-2.2 is negative). 
Remember that all consulted Advisors have to provide the severe treatment if the problem is 
severe. 
If an Adviser is not consulted in a period, his income from that period is 0 points. 
 
The History Table 
In order for the participants to keep track of what has happened in previous periods, both the 
Advisers and the Clients are shown history tables on the left part of their screen. These tables are 
mere summaries. They do not provide information in addition to what has been told during the 
experiment, with one exception: The History Table for both Clients and Advisers shows the 
number of Clients that chose to consult a particular Adviser in all past periods. 
 
These are the rules. You can trust us that everything will happen exactly according to these rules. 
Take your time to go over the instructions once again and feel free to ask questions. But don’t 
shout! Simply raise your hand. 
39 
 
Income Table
Adviser provides No Treatment
or 0 if negative
0 0
Severe Treatment 17 17
Mild Treatment - - 10
Client Advisor Client Advisor
Income Income Income Income
Note: The table shows the income for an Advisor from being consulted by one Client
True severity of problem
Severe Mild
7*
5
treatmentssevereof#
10
⋅⋅⋅⋅
− 7*
5
treatmentssevereof#
10
⋅⋅⋅⋅
−
7*
5
treatmentssevereof#
2
⋅⋅⋅⋅
− 7*
5
treatmentssevereof#
9
⋅⋅⋅⋅
−
7*
5
treatmentssevereof#
10
⋅⋅⋅⋅
−
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Appendix B – Screenshots 
Figure B1: Screenshot physician (adviser) – condition BASE and INS 
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Figure B2: Screenshot physician (adviser) – condition COMP and INS-COMP 
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Figure B3: Screenshot patient (client) – condition BASE and INS 
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Figure B4: Screenshot patient (client) – condition COMP and INS-COMP 
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Appendix C – Tables including / excluding severe periods 
 
Table C1: Aggregated results (including and excluding severe periods) 
 Severe 
periods BASE COMP INS INS-COMP 
(1) consulting rate 
included 40.67 54.67 55.33 83.14 
excluded 40.14 53.56 55.48 83.42 
(2) overtreatment rate 
included 18.03 4.88 49.40 23.83 
excluded 26.28 7.16 70.86 34.15 
(3) efficiency rate 
included 61.17 70.50 71.47 89.46 
excluded 67.08 74.46 75.51 90.88 
(4) correct treatment   
 rate (CTR) 
included 33.34 52.00 28.00 63.34 
excluded 29.59 49.73 16.16 54.93 
(5) average earnings   
 physicians 
included 9.12 11.46 14.37 19.10 
excluded 7.92 9.37 13.83 17.23 
(6) average earnings  
 patients 
included 6.76 7.23 5.67 6.43 
excluded 8.66 9.27 6.80 7.84 
Notes: Table shows averages over all 30 periods and 7 groups per treatment. The rates in the first eight lines 
are indicated in percent: (1) is the share of consulting patients, (2) is the share of consulted physicians who 
give severe treatment when the problem is mild, where the average rate (2) is weighted by the number of 
consultations per session and period. (3) is sum of actual earnings over sum of potential earnings, (4) is the 
share of all interactions with needed treatment provided. Average earnings in (5) and (6) are indicated in 
points. The data for “included” is reprinted from table 2 in the main text. 
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Table C2: Wilcoxon-Mann-Whitney test – emp. z-values (including / excluding sv. periods) 
  Impact of competition   Impact of insurance 
 
 Without insurance   
With  
insurance  
 Without 
competition 
With  
competition 
 Severe 
periods 
BASE vs. 
COMP  
INS vs.  
INS-COMP 
 BASE vs.         
INS 
COMP vs.  
INS-COMP 
(1) consulting rate 
included -1.28  -2.62 ***   -1.09  -2.75 ***  
excluded -1.09 -2.62 ***  -1.15 -2.75 *** 
(2) overtreatment 
rate 
included      2.88 ***  2.36 **  -3.13 *** -3.13 *** 
excluded  3.00 ***   2.36 **   - 3.13 ***  -3.07 ***  
(3) efficiency rate 
included -1.34  -2.62 ***   -1.09  -2.75 ***  
excluded -1.09 -2.62 ***  -1.15 -2.75 *** 
(4) correct treatment   
 rate (CTR) 
included -1.34 -2.50 **   0.70 -0.96 
excluded -1.60  -2.36 **    0.83  -0.58  
(5) average earnings   
 physicians 
included -1.09  -2.49 **   -1.98 **  -2.88 ***  
excluded -0.58 -1.85 *  -2.234 ** -3.13 *** 
(6) average earnings  
 patients 
included -1.60  -1.47   2.88 ***   1.73 *  
excluded -3.00 *** -1.34  3.13 ***  2.88 *** 
Note: see table C1 for explanations. * p ≤ 0.1;   ** p ≤ 0.05;  *** p ≤ 0.01 
 
Table C3: Robust rank order test – Empirical Û-values 
 Impact of competition   Impact of insurance 
 Without insurance   
With  
insurance  
 Without 
competition 
With  
competition 
 BASE vs. COMP  INS vs.  INS-COMP  BASE vs.  INS COMP vs.  INS-COMP 
(1)  consulting rate -1.32 -4.63 ***  -1.05 -6.02 *** 
(2)  overtreatment rate  14.32 ***  3.04 **   n. d. ***  -24.98 *** 
(3)  efficiency rate  -1.40 * -4.69 ***  -1.05 -6.14 *** 
(4)  correct treatment rate (CTR) -1.81 ** -3.04 **   0.72 -0.53 
(5)  average earnings physicians  -1.05 -4.22 ***  -2.51 ** -8.64 *** 
(6)  average earnings patients  -1.81 ** -1.44 *   8.64 ***  1.99 ** 
Note: If the highest observation in one condition is smaller than the lowest observation in the other treatment, 
the test statistic of the robust rank order test is not defined. We denote these cases with  
n. d. and three stars. * p ≤ 0.1;   ** p ≤ 0.05;  *** p ≤ 0.01 
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Table C4: Regression coefficients (panel probit regression)  
 Dep. variable Consulting Overtreatment 
      (A)      (B)     (C)     (D)     (E)     (F) 
1 COMP  0.66***  0.74***  0.67** -0.34 -0.38  0.04 
2 INS  0.78***  0.80*** -0.20  1.21***  1.19***  1.44*** 
 Obs_shares  0.16  0.12  0.12 -0.80*** -0.75** -0.84** 
3 Period -0.02*** -0.02*** -0.02***  0.01**  0.01**  0.01*** 
4 Sev_high -0.82*** -0.81*** -0.76*** - - - 
5 #Pat_high - - - 0.27*** 0.27*** 0.62*** 
6 COMP x Sev_high - - -0.34 - - - 
7 INS x Sev_high - -  0.63*** - - - 
8 COMP x #Pat_high - - - - - -0.54*** 
9 INS x #Pat_high - - - - - -0.00 
10 COMP x INS - -  0.67** - - -0.42 
 Obs_shares x INS - -  0.01    0.18 
11 Intercept  0.66***  0.32  0.56* -0.75*** -1.56*** -1.76*** 
 Controls No Yes Yes No Yes Yes 
 No. of obs. 5346 5346 5346 1632 1632 1632 
 AIC 0.958 0.958 0.957 0.914 0.910 0.909 
Notes: Table shows regression coefficients from a panel probit regression. Dependent variables are 
dummies which indicate in (A) to (C) whether or not a patient consults a physician, and in (D) to (F) 
whether or not a physician overtreats conditional on being consulted. COMP,  INS and Obs_shares are 
dummies indicating the treatment variations. COMP indicates whether patients can choose their 
physician (i.e. equals 1 for COMP, COMP_nms, INS-COMP and INS-COMP_nms), INS denotes the 
presence of the insurance, and Obs_shares indicates whether market shares are observable (i.e. equals 
1 for COMP and INS-COMP). Sev_high = 1 when the rate of severe treatments a patient got so far 
exceeds its mathematical expectation, i.e. 1/3, and = 0 if it is smaller. #Pat_high = 1 if the physician was 
consulted by more than one patient, and = 0 otherwise (i.e. if she was consulted by one patient only). 
Controls “Yes” indicates that the regression includes gender and field of study.  
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Appendix D – Consulting rate in BASE by market 
 
Figure D1: Heterogenous consulting rates across markets 
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Appendix E – Derivation of the equilibrium in INS 
We solve the one-shot game by backwards induction. As in the baseline condition, in the last 
move, physicians provide the severe treatment, i.e. physicians’ incentives do not change with 
insurance. The decision problem of patient 𝑖 is as follows: Denote by  𝜎−𝑖 ∈ {1, 2, 3, 4} the 
number of other patients in the market who consult. As physicians always provide the severe 
treatment in equilibrium, 𝜎−𝑖 is the total number of severe treatments if patient 𝑖 does not 
consult. His expected payoff if he does not consult a physician is: 
𝐸𝜋𝑖(𝜎−𝑖, ¬𝐶) = 13 ⋅ �2 − 𝜎−𝑖5 ⋅ 7� + 23 ⋅ �9 − 𝜎−𝑖5 ⋅ 7� = 203 − 𝜎−𝑖5 ⋅ 7 
The expected payoff of patient 𝑖 if he does consult the physician is calculated analogously. 
Now, 𝜎−𝑖 + 1 is the total number of severe treatments. As the costs of a severe treatment are 
socialized, the (expected) payoff does no longer depend on the severity of the problem: 
𝐸𝜋𝑖(𝜎−𝑖,𝐶) = 10 − 𝜎−𝑖 + 15 ⋅ 7 = 10 − �𝜎−𝑖5 ⋅ 7 + 75� = 435 − 𝜎−𝑖5 ⋅ 7 
As patient 𝑖’s (expected) payoff for consulting is greater than the expected payoff for not 
consulting for all 𝜎−𝑖 ∈ {1, 2,3, 4}, it is dominant to consult. The same holds true for all other 
patients in the market. Therefore, a unique equilibrium prevails in which patients consult the 
assigned physician and physicians provide a severe treatment. 
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Appendix F –  Supplementary test results for the control treatments 
 
Table F1: Wilcoxon-Mann-Whitney (WMW) test – empirical z-values 
  Impact of insurance 
 
 (1) 
Without 
competition 
(2) 
With 
competition 
but without 
market shares 
(3) 
With 
competition  
and market 
shares 
 
 
BASE vs. INS COMP_nms vs.  INS-COMP_nms 
COMP vs.  
INS-COMP 
(1) consulting rate  -1.09  -3.01*** -2.75 ***  
(2) overtreatment rate  -3.13 ***  -0.96 -3.07 ***  
(3) efficiency rate  -1.09  -3.00*** -2.75 ***  
(4) correct treatment rate (CTR)   0.83  -0.70 -0.58  
(5) average earnings physician  -1.98 **  -3.13*** -2.88 ***  
(6) average earnings patients   2.88 ***  1.85*   1.73 *  
Notes: see table 2 in the main text for explanations of variables. Positive numbers indicate that the 
value of the variable is larger in the treatment condition named first, and vice versa for negative 
values. Numbers in column (1) and (3) reprint columns (3) and (4) from table 3 in the main text.  
* p ≤ 0.1;   ** p ≤ 0.05;  *** p ≤ 0.01 
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Appendix G – Market outcomes over time  
Figure G1 shows the average consulting rate over time in conditions without insurance; figure 
G2 in the conditions with insurance. In BASE, the consulting rate clearly decreases over time. It 
is at 57.1 percent in the first three periods and declines to less than a third of that (16.2) 
percent in the last three. As patients cannot unambiguously tell whether they have been 
overtreated due to the very nature of the credence good studied here (they can only compare 
the number of severe treatments they got with the probability of a severe treatment), they 
have to learn that consulting is not well-advised from experience, and such learning takes time. 
Figure G1: Consulting rate over time (conditions without insurance) 
 
In COMP the consulting rate has an inverse u-shape. It starts at around 40 percent in the 
first 3 periods, peaks at around 70 percent in the middle periods, and falls to around 30 percent 
in the last three periods. The decline in the second half seems to be driven by the physicians’ 
diminishing incentive to maintain a good reputation over time.  
In the treatments with insurance, the consulting rate seems to have no clear trend. It 
fluctuates between 40% and 60% in INS and remains at considerably higher levels of between 
70% and 90% in INS-COMP. This finding is in line with our expectation that both insurance and 
competition have a positive impact on consulting. In all conditions (except for INS-COMP_nms) 
we observe pronounced end game effects as reputational concerns wither. 
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Figure G2: Consulting rate over time (conditions with insurance) 
 
Figure G3 and G4 show the smoothed overtreatment rate over time.30 The figures shows 
that competition massively reduces overtreatment, especially in the presence of insurance 
(compare INS vs. INS-COMP). In COMP, overtreatment is below 20 percent in all periods (except 
for the pronounced endgame effect), and falls to levels close to zero in most periods in the 
second half of the experiment. Remarkably, the effect of competition is immediate (absent 
insurance): the overtreatment rate is lower in COMP than in the other treatments already in 
the first period. This suggests that physicians anticipate the competitive pressure resulting from 
the free choice of physicians from the very beginning. The figure also shows the rather 
detrimental effect of insurance on overtreatment. After some periods and with few exceptions 
later on, the overtreatment rate hovers around 60 to 90 percent in INS (see line with triangles). 
Physicians seem to quickly learn that patients have an incentive to consult and do not seem to 
care much about being overtreated. The negative effect of insurance (second degree moral 
hazard) seems to slightly dominate the beneficial effect of competition by disciplining service 
providers in our setting (overtreatment in INS-COMP tends to be slightly higher than in BASE). 
 
                                                     
30  We show smoothed values for the overtreatment rate here to facilitate readability of the figure. This rate 
fluctuates much more than the consulting rate over time, especially in the conditions with low consulting rates.  
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Figure G3: Overtreatment rate over time (conditions without insurance) 
 
Notes: Figure shows smoothed overtreatment rate (moving average with a weight of 0.25 on the preceding and the 
consecutive period, except for periods 1 and 30)  
Figure G4: Overtreatment rate over time (conditions with insurance) 
 
Notes: Figure shows smoothed overtreatment rate (moving average with a weight of 0.25 on the preceding and the 
consecutive period, except for periods 1 and 30)   
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Appendix H – Overtreatment rates by physician market share  
Table H1 addresses the question of whether more popular physicians are less likely to behave  
opportunistically or, conversely, whether patients tend to consult those physicians who are less 
prone to behave opportunistically (our analysis cannot distinguish between the two explana-
tions). Specifically, the table shows average overtreatment rates by the number of consulting 
patients. For example, in BASE, 18.3 percent of all physicians with exactly one consulting 
patient overtreat that patient. The column marked “overall” recapitulates the numbers from 
the second line in table 2 in the main text.  
Table H1: Overtreatment rate (in percent) by number of consulting patients 
  
Overall 
 
Number of consulting patients 
 one  two three or more 
BASE 26.3 18.3 27.2 40.9 
COMP_nms 20.7 30.4 16.4 9.5 
COMP 7.2 9.3 7.3 0.0 
INS 70.9 65.9 74.4 75.0 
INS-COMP_nms 44.4 57.2 48.0 29.0 
INS-COMP 34.2 43.4 31.8 29.8 
Notes: the share of “unemployed” physicians, i.e. the share of physicians with zero patients was 53.7 in 
BASE, 51.60 in COMP_nms, 37.7 in COMP, 36.5 in INS, 28.77 in INS-COMP_nms and 19.2 in INS-COMP 
(see table E3 for details). The column marked “overall” shows overtreatment rates conditional on being 
consulted, i.e. it shows the share of consulted physicians who give severe treatment when the problem 
is mild. 
The table illustrates the disciplining effect of competition on physicians. In the conditions 
without competition, the overtreatment rate of physicians with two, and of those with three 
and more patients, are higher than the overall overtreatment rate. For example, the 
overtreatment rate among physicians with two patients consulting in INS is more than twice the 
rate in INS-COMP (74.4 vs. 31.8 percent), and the overtreatment rate in BASE it is about four 
times the rate in COMP (27.2 vs. 7.3 percent). The differences are even more pronounced in the 
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(rare) cases where a physician has three or more patients consulting.31 These results are 
consistent with our findings from in table 6. These regressions show that overtreatment is 
significantly lower in the treatments with competition (see line 1). It is generally higher among 
physicians that are consulted by many patients (see line 6), but that this effect is significantly 
reduced in the presence of competition (see col. F, line 9). 
We find that the “market concentration” (i.e. the concentration of patients on particular 
physicians) tends to be larger in the treatments with competition. This suggests that patients 
succeed in selecting physicians who provide more adequate treatments. For example, the share 
of physicians with two or more consulting agents is about 50 percent larger in COMP than in 
BASE (22.8 vs. 15.1 percent), and it is almost twice as large in INS-COMP as in INS (44.5 vs. 23.3 
percent). 
Table H2: Distribution of physicians’s market shares 
 
Number of consulting patients 
 zero one  two three or more 
BASE 53.65 31.28 10.05 5.02 
COMP_nms 51.60 30.82 12.56 5.02 
COMP 37.67 39.50 18.72 4.11 
INS 36.53 40.18 17.81 5.48 
INS-COMP_nms 28.77 31.51 23.29 16.44 
INS-COMP 19.18 36.30 33.79 10.73 
Notes: The theoretical benchmark of random assignment (if all patients consult the physician they 
have been assigned to) is 13.17 (zero patients), 32.92 (one patient), 32.92 (two patients) and 20.99 
(three or more patients). 
 
 
                                                     
31  This is the case in 4 to 6 percent of the periods in all conditions except for INS-COMP where physicians have 
three or more patients consulting in about 10 percent of the periods. For details on the distribution of 
physicians’ market shares, see table H2. 
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